MCID: WLD002
MIFTS: 62

Waldenstrom Macroglobulinemia malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Waldenstrom Macroglobulinemia

About this section
Sources:
11Disease Ontology, 13DISEASES, 25Genetics Home Reference, 26GTR, 29ICD10, 30ICD10 via Orphanet, 31ICD9CM, 34LifeMap Discovery®, 38MeSH, 39MESH via Orphanet, 44NCIt, 47NIH Rare Diseases, 49Novoseek, 53Orphanet, 61SNOMED-CT, 67UMLS, 68UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Waldenstrom Macroglobulinemia:

Name: Waldenstrom Macroglobulinemia 34 47 25 49 38 67
Lymphoplasmacytic Lymphoma 11 47 13
Macroglobulinemia of Waldenstrom 47 25
Waldenstrom's Macroglobulinemia 25 26
Waldenström Macroglobulinemia 25 53
 
Malignant Lymphoma - Lymphoplasmacytic 67
Waldenström's Macroglobulinemia 11
Waldenstrom's Macroglobulinaemia 47
Waldenstrom's Syndrome 47
Wm 25

Characteristics:

Orphanet epidemiological data:

53
waldenström macroglobulinemia:
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/1000000 (Europe),1-9/100000 (France),1-9/1000000 (United States),1-9/1000000 (United Kingdom),1-9/1000000 (Spain),1-9/100000 (Europe); Age of onset: Elderly; Age of death: elderly

Classifications:



External Ids:

Disease Ontology11 DOID:0050747
ICD1029 C88.0
ICD9CM31 273.3
MeSH38 D008258
Orphanet53 ORPHA33226
MESH via Orphanet39 D008258
UMLS via Orphanet68 C0024419
ICD10 via Orphanet30 C88.0
UMLS67 C0024419, C2936755

Summaries for Waldenstrom Macroglobulinemia

About this section
Genetics Home Reference:25 Waldenström macroglobulinemia is a rare blood cell cancer characterized by an excess of abnormal white blood cells called lymphoplasmacytic cells in the bone marrow. This condition is classified as a lymphoplasmacytic lymphoma. The abnormal cells have characteristics of both white blood cells (lymphocytes) called B cells and of more mature cells derived from B cells known as plasma cells. These abnormal cells produce excess amounts of IgM, a type of protein known as an immunoglobulin; the overproduction of this large protein is how the condition got its name ("macroglobulinemia").

MalaCards based summary: Waldenstrom Macroglobulinemia, also known as lymphoplasmacytic lymphoma, is related to lymphoplasmacytic lymphoma without igm production and weill-marchesani syndrome 1, recessive, and has symptoms including leukemia, abnormal immunoglobulin level and gingival bleeding. An important gene associated with Waldenstrom Macroglobulinemia is MYD88 (Myeloid Differentiation Primary Response 88), and among its related pathways are CD40/CD40L signaling and A-beta Pathways: Uptake and Degradation. The drugs chlorambucil and thalidomide have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related mouse phenotypes are hematopoietic system and immune system.

Disease Ontology:11 A B-cell lymphocytic neoplasm characterized by an uncontrolled increase of B-cells.

Related Diseases for Waldenstrom Macroglobulinemia

About this section

Diseases in the Waldenstrom Macroglobulinemia family:

Macroglobulinemia, Waldenstrom 2 Macroglobulinemia, Waldenstrom 1

Diseases related to Waldenstrom Macroglobulinemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 74)
idRelated DiseaseScoreTop Affiliating Genes
1lymphoplasmacytic lymphoma without igm production12.0
2weill-marchesani syndrome 1, recessive11.6
3macroglobulinemia11.6
4macroglobulinemia, waldenstrom 111.4
5gamma heavy chain disease10.6CD40LG, MYD88
6arteriosclerosis10.6CD40LG, MYD88
7delta chain disease10.5CD40LG, MYD88
8plasmodium malariae malaria10.5CD40LG, MYD88
9ischemic optic neuropathy10.5CXCR4, PAX5
10immunoglobulin alpha deficiency10.5CD40, CD40LG
11cockayne syndrome10.5CD40, CD40LG
12polyembryoma of the ovary10.4CD40LG, PAX5
13lambda 5 deficiency10.4CD40, CD40LG
14hypoparathyroidism, x-linked10.4CD40, CD40LG
15melanoma metastasis10.4CD40LG, MYD88
16caplan's syndrome10.4CD40LG, HAS1
17pediatric t-cell leukemia10.4IGHM, MYD88
18binocular vision disease10.4CD40LG, MYD88
19alcoholic neuropathy10.4CD40LG, IGHM
20spinal polio10.4CD40, CD40LG
21generalized atherosclerosis10.3CD40LG, CXCR4, MYD88
22smoldering myeloma10.3CD40LG, ITGAE
23taylor's syndrome10.3CD40LG, CXCR4, HAS1
24chromosome 13q14 deletion syndrome10.3IGHM, ZAP70
25recombinase activating gene 2 deficiency10.3CD40, ZAP70
26uterine inversion10.2CD40, CD40LG, MYD88
27hemolytic anemia10.2CD40LG, PAX5, ZAP70
28organ system benign neoplasm10.2CD40LG, PAX5, ZAP70
29lymphoma10.2
30spastic paraplegia 8, autosomal dominant10.2CD40, CD40LG, PAX5
31lipid pneumonia10.2MYD88, PAX5
32solitary bone cyst10.1CD40, ITGAE
33cpt deficiency, hepatic, type ia10.1CD40, CD40LG, CXCR4
34nasopharyngitis10.1CD40LG, MYD88
35syngnathia cleft palate10.1ITGAE, PAX5
36lipid-rich breast carcinoma10.1CD40, CD40LG
37steroid-induced glaucoma10.1CD40LG, ITGAE
38multiple myeloma10.1
39disease_ontology10.1CD40LG, CXCR4, HAS1, MYD88
40membranoproliferative glomerulonephritis10.1CD27, CD40LG
41metabolic acidosis10.0CD40LG, CXCR4, MYD88, PAX5
42ovarian endometrioid malignant adenofibroma10.0CD40LG, ITGA4
43ehlers-danlos syndrome, musculocontractural type10.0CD27, CXCR4
44tularemia9.9CD27, CD40, CD40LG
45bipolar disorder9.9CD40, CD40LG, MYD88, PAX5
46leukemia9.9
47congenital symblepharon9.9CD27, CD40, CD40LG
48hodgkin lymphoma9.8
49temporal arteritis9.8
50pulmonary hypertension9.8

Comorbidity relations with Waldenstrom Macroglobulinemia via Phenotypic Disease Network (PDN):


Deficiency AnemiaNeutropenia
Heart DiseaseAcute Cystitis

Graphical network of the top 20 diseases related to Waldenstrom Macroglobulinemia:



Diseases related to waldenstrom macroglobulinemia

Symptoms for Waldenstrom Macroglobulinemia

About this section

Human phenotypes related to Waldenstrom Macroglobulinemia:

 63 53 (show all 51)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 leukemia63 53 hallmark (90%) Very frequent (99-80%) HP:0001909
2 abnormal immunoglobulin level63 hallmark (90%) HP:0010701
3 gingival bleeding63 53 typical (50%) Frequent (79-30%) HP:0000225
4 pallor63 53 typical (50%) Frequent (79-30%) HP:0000980
5 abnormality of neutrophils63 53 typical (50%) Frequent (79-30%) HP:0001874
6 normocytic anemia63 53 typical (50%) Frequent (79-30%) HP:0001897
7 respiratory insufficiency63 53 typical (50%) Frequent (79-30%) HP:0002093
8 vertigo63 53 typical (50%) Frequent (79-30%) HP:0002321
9 hypercoagulability63 53 typical (50%) Frequent (79-30%) HP:0100724
10 renal insufficiency63 53 occasional (7.5%) Occasional (29-5%) HP:0000083
11 hearing impairment63 53 occasional (7.5%) Occasional (29-5%) HP:0000365
12 epistaxis63 53 occasional (7.5%) Occasional (29-5%) HP:0000421
13 proptosis63 53 occasional (7.5%) Occasional (29-5%) HP:0000520
14 cutis marmorata63 53 occasional (7.5%) Occasional (29-5%) HP:0000965
15 urticaria63 53 occasional (7.5%) Occasional (29-5%) HP:0001025
16 congestive heart failure63 53 occasional (7.5%) Occasional (29-5%) HP:0001635
17 splenomegaly63 53 occasional (7.5%) Occasional (29-5%) HP:0001744
18 subcutaneous hemorrhage63 occasional (7.5%) HP:0001933
19 malabsorption63 53 occasional (7.5%) Occasional (29-5%) HP:0002024
20 anorexia63 53 occasional (7.5%) Occasional (29-5%) HP:0002039
21 migraine63 53 occasional (7.5%) Occasional (29-5%) HP:0002076
22 abnormality of the pleura63 occasional (7.5%) HP:0002103
23 pulmonary infiltrates63 53 occasional (7.5%) Occasional (29-5%) HP:0002113
24 gastrointestinal hemorrhage63 53 occasional (7.5%) Occasional (29-5%) HP:0002239
25 hepatomegaly63 53 occasional (7.5%) Occasional (29-5%) HP:0002240
26 incoordination63 occasional (7.5%) HP:0002311
27 memory impairment63 53 occasional (7.5%) Occasional (29-5%) HP:0002354
28 vasculitis63 53 occasional (7.5%) Occasional (29-5%) HP:0002633
29 cerebral ischemia63 occasional (7.5%) HP:0002637
30 lymphadenopathy63 53 occasional (7.5%) Occasional (29-5%) HP:0002716
31 abnormality of temperature regulation63 occasional (7.5%) HP:0004370
32 reduced consciousness/confusion63 53 occasional (7.5%) Occasional (29-5%) HP:0004372
33 cranial nerve paralysis63 53 occasional (7.5%) Occasional (29-5%) HP:0006824
34 abnormality of the retinal vasculature63 53 occasional (7.5%) Occasional (29-5%) HP:0008046
35 peripheral neuropathy63 53 occasional (7.5%) Occasional (29-5%) HP:0009830
36 edema of the lower limbs63 53 occasional (7.5%) Occasional (29-5%) HP:0010741
37 periorbital edema63 53 occasional (7.5%) Occasional (29-5%) HP:0100539
38 cryoglobulinemia63 53 occasional (7.5%) Occasional (29-5%) HP:0100778
39 retinal hemorrhage53 Occasional (29-5%)
40 purpura53 Occasional (29-5%)
41 ataxia53 Occasional (29-5%)
42 stroke53 Occasional (29-5%)
43 fever53 Occasional (29-5%)
44 diarrhea53 Occasional (29-5%)
45 pleural effusion53 Occasional (29-5%)
46 lymphoma53 Very frequent (99-80%)
47 recurrent infections53 Occasional (29-5%)
48 elevated erythrocyte sedimentation rate53 Occasional (29-5%)
49 waldenstrom macroglobulinemia53 Very frequent (99-80%)
50 multifocal epileptiform discharges53 Occasional (29-5%)
51 fatigue53 Occasional (29-5%)

Drugs & Therapeutics for Waldenstrom Macroglobulinemia

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Evista16 43 RALOXIFENE HYDROCHLORIDE Eli Lilly September 2007
FDA Label: Evista
Disease/s that Drug Treats:osteoporosis and reduction of breast cancer risk in postmenopausal women
Indications and Usage:16 EVISTA is an estrogen agonist/antagonist indicated for Treatment and prevention of osteoporosis in postmenopausal women.(1.1)
DrugBank Targets:14 1. Estrogen receptor;2. Estrogen receptor beta
Mechanism of Action:16 
Target: estrogenic pathways
Action: can be an activator or antooagonist
FDA: Decreases in estrogen levels after oophorectomy or menopause lead to increases in bone resorption andaccelerated bone loss. Bone is initially lost rapidly because the compensatory increase in bone formation isinadequate to offset resorptive losses. In addition to loss of estrogen, this imbalance between resorption andformation may be due to age-related impairment of osteoblasts or their precursors. In some women, these changeswill eventually lead to decreased bone mass, osteoporosis, and increased risk for fractures, particularly of the spine,hip, and wrist. Vertebral fractures are the most common type of osteoporotic fracture in postmenopausal women.The biological actions of raloxifene are largely mediated through binding to estrogen receptors. This bindingresults in activation of certain estrogenic pathways and blockade of others. Thus, raloxifene is an estrogenagonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM).Raloxifene decreases resorption of bone and reduces biochemical markers of bone turnover to thepremenopausal range. These effects on bone are manifested as reductions in the serum and urine levels of boneturnover markers, decreases in bone resorption based on radiocalcium kinetics studies, increases in bone mineraldensity (BMD), and decreases in incidence of fractures.
2
Imbruvica16 43 IBRUTINIB Pharmacyclics November of 2013/ February 2014
FDA Label: Imbruvica
Disease/s that Drug Treats:mantle cell lymphoma/chronic lymphocytic leukemia
Indications and Usage:16 IMBRUVICA is a kinase inhibitor indicated for the treatment of patients with: Mantle cell lymphoma (MCL) who have received at least one priortherapy (1.1).Accelerated approval was granted for this indication based on overallresponse rate. Continued approval for this indication may be contingentupon verification of clinical benefit in confirmatory trials. Chronic lymphocytic leukemia (CLL) who have received at least oneprior therapy (1.2). Chronic lymphocytic leukemia with 17p deletion (1.3). Waldenström’s macroglobulinemia (WM) (1.4).
DrugBank Targets:14 1. Tyrosine-protein kinase BTK
Mechanism of Action:16 
Target: Bruton's tyrosine kinase (Btk)
Action: selective inhibitor
FDA: Ibrutinib is a small-molecule inhibitor of BTK. Ibrutinib forms a covalent bond with a cysteineresidue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is asignaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTK’srole in signaling through the B-cell surface receptors results in activation of pathways necessaryfor B-cell trafficking, chemotaxis, and adhesion. Nonclinical studies show that ibrutinib inhibitsmalignant B-cell proliferation and survival in vivo as well as cell migration and substrateadhesion in vitro.
3
Inlyta16 43 AXITINIB Pfizer January 2012
FDA Label: Inlyta
Disease/s that Drug Treats:advanced renal cell carcinoma
Indications and Usage:16 INLYTA is a kinase inhibitor indicated for the treatment of advancedrenal cell carcinoma after failure of one prior systemic therapy. (1)
DrugBank Targets:14 1. Vascular endothelial growth factor receptor 1;2. Vascular endothelial growth factor receptor 2;3. Vascular endothelial growth factor receptor 3
Mechanism of Action:16 
Target: receptor tyrosine kinases
Action: inhibitor
FDA: Axitinib has been shown to inhibit receptor tyrosine kinases including vascular endothelial growthfactor receptors (VEGFR)-1, VEGFR-2, and VEGFR-3 at therapeutic plasma concentrations. Thesereceptors are implicated in pathologic angiogenesis, tumor growth, and cancer progression. VEGFmediatedendothelial cell proliferation and survival were inhibited by axitinib in vitro and in mousemodels. Axitinib was shown to inhibit tumor growth and phosphorylation of VEGFR-2 in tumor xenograftmouse models.
4
Torisel16 43 TEMSIROLIMUS Wyeth May 2007
FDA Label: Torisel
Disease/s that Drug Treats:renal cell carcinoma
Indications and Usage:16 TORISEL® is a kinase inhibitor indicated for the treatment of advanced renalcell carcinoma. (1)
DrugBank Targets:14 1. Serine/threonine-protein kinase mTOR
Mechanism of Action:16 
Target: mTOR
Action: inhibitor
FDA: Temsirolimus is an inhibitor of mTOR (mammalian target of rapamycin). Temsirolimus binds toan intracellular protein (FKBP-12), and the protein-drug complex inhibits the activity of mTORthat controls cell division. Inhibition of mTOR activity resulted in a G1 growth arrest in treatedtumor cells. When mTOR was inhibited, its ability to phosphorylate p70S6k and S6 ribosomalprotein, which are downstream of mTOR in the PI3 kinase/AKT pathway was blocked. Inin vitro studies using renal cell carcinoma cell lines, temsirolimus inhibited the activity of mTORand resulted in reduced levels of the hypoxia-inducible factors HIF-1 and HIF-2 alpha, and thevascular endothelial growth factor.

Drugs for Waldenstrom Macroglobulinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 369)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
ThiotepaapprovedPhase 4, Phase 2, Phase 321652-24-45453
Synonyms:
 
Thioplex
2
Cytarabineapproved, investigationalPhase 4, Phase 1, Phase 21093147-94-46253
Synonyms:
(beta-D-Arabinofuranosyl)cytosine
(beta-D-arabinofuranosyl)cytosine
1-.beta.-D-arabinofuranosyl-cytosine
1-Arabinofuranosylcytosine
1-beta -D-Arabinofaranosylcytosine
1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1-beta -D-Arabinofuranosylcytosine
1-beta-D-Arabinofaranosylcytosine
1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1-beta-D-Arabinofuranosyl-Cytosine
1-beta-D-Arabinofuranosylcytosine
1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside
1-beta-D-Arabinosyl-Cytosine
1-beta-D-Arabinosylcytosine
147-94-4
1beta -Arabinofuranasylcytosine
1beta -D-Arabinofuranosylcytosine
1beta -D-Arabinosylcytosine
1beta-Arabinofuranasylcytosine
1beta-D-Arabinofuranosylcytosine
1beta-D-Arabinosylcytosine
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl- [CAS]
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl
30399_FLUKA
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine
4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone
4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one
69-74-9 (hydrochloride)
AC-1075
AC1L1M4F
AC1Q52OJ
AI3-52329
AR3
Alexan
Ara-C
Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine
Ara-Cytidine
AraC
Arabinocytidine
Arabinofuranosyl Cytidine
Arabinofuranosylcytosine
Arabinosyl Cytosine
Arabinosylcytosine
Arabitin
Aracytidine
Aracytin
Aracytine
Arafcyt
BIDD:GT0371
BIDD:PXR0139
BTB15125
Beta-cytosine arabinoside
C02961
C1768_SIGMA
C2035
C9H13N3O5
CCRIS 913
CHEBI:28680
CHEMBL803
CHX 3311
CID6253
CPD000449317
CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9)
Citarabina
Citarabina [INN-Spanish]
Cytarabin
Cytarabina
Cytarabine
Cytarabine (JP15/USP/INN)
 
Cytarabine [USAN:INN:BAN:JAN]
Cytarabine liposome injection
Cytarabinoside
Cytarabinum
Cytarabinum [INN-Latin]
Cytarbel
Cytonal
Cytosar
Cytosar-U
Cytosine 1-beta-D-arabinofuranoside
Cytosine arabinofuranoside
Cytosine arabinose
Cytosine arabinoside
Cytosine arabinoside (VAN)
Cytosine beta-D-arabinofuranoside
Cytosine beta-D-arabinofuranoside hydrochloride
Cytosine beta-D-arabinoside
Cytosine, beta -D-arabinoside
Cytosine, beta-D-arabinoside
Cytosine-1-beta-D-arabinofuranoside
Cytosine-1-beta-D-arabinofuranoside hydrochloride
Cytosine-beta -D-arabinofuranoside
Cytosine-beta -arabinoside
Cytosine-beta-D-arabinofuranoside
Cytosine-beta-arabinoside
Cytosinearabinoside
D00168
DB00987
DepoCyte
Depocyt
Depocyt (TN)
Depocyt (liposomal)
Depocyte
EINECS 205-705-9
Erpalfa
FT-0082880
HMS2051K19
HMS2090A18
HSDB 3049
Intrathecal (injected into the spinal fluid) DepoCyt
Intrathecal cytarabine (also known as ara-C)
Iretin
LS-860
Lopac0_000316
MLS000758310
MLS001066340
MolPort-001-792-509
NCGC00093356-03
NCGC00093356-04
NCGC00093356-05
NCI-C04728
NSC 287459
NSC287459
S1648_Selleck
SAM001247012
SMR000449317
SR-01000075773-3
Spongocytidine
TL8001048
Tarabine
U 19920A
U-19,920
U-19920
UNII-04079A1RDZ
Udicil
ZINC03795098
beta -D-arabinosylcytosine
beta -arabinosylcytosine
beta -cytosine arabinoside
beta-Ara C
beta-Ara c
beta-Arabinosylcytosine
beta-Cytosine arabinoside
beta-D-Arabinosylcytosine
cytarabine
cytarabine liposome injection
cytosine-β-D-arabinofuranoside
3
rituximabapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 11654174722-31-710201696
Synonyms:
AntiCD20
IDEC-102
IDEC-C2B8
 
Ig gamma-1 chain C region
MabThera
Mabthera
Rituxan
rituximab
4
Dexamethasoneapproved, investigational, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1208450-02-25743
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
137098-19-2
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16α-Methyl-9α-fluoro-1-dehydrocortisol
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-fluoro-16alpha-methyl-Prednisolone
9α-Fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
AI3-50934
Adexone
Aeroseb-D
Aeroseb-Dex
Aeroseb-dex
Ak Dex Oph Otic Soln 0.1%
Alcon Brand of Dexamethasone
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (Veterinary)
Azium (veterinary)
BIDD:ER0494
BIDD:PXR0060
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
Bisu DS
Bisu Ds
C15643
C22H29FO5
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
CPD-10549
CPD001227192
Calonat
Corson
Corsone
Cortisumman
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
DEX
DEXA
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
DXM
DXMS
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-LA
Decadron-La
Decagel
Decaject
Decaject L.A.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [DCIT]
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
Dex-Ide
Dex-ide
Dexa
Dexa Mamallet
Dexa mamallet
Dexa-Cortidelt
Dexa-Cortisyl
Dexa-Mamallet
Dexa-Scheroson
Dexa-Sine
Dexa-cortidelt
Dexa-cortisyl
Dexa-scheroson
Dexa-sine
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexacortin
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
 
Dexameth
Dexamethansone
Dexamethasone
Dexamethasone (JP15/USP/INN)
Dexamethasone Acetate
Dexamethasone Alcohol
Dexamethasone Base
Dexamethasone Intensol
Dexamethasone Sodium Phosphate
Dexamethasone [INN:BAN:JAN]
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexason
Dexasone
Dexasone 0.5mg
Dexasone 0.75mg
Dexasone 4mg
Dexasporin
Dexinolon
Dexinoral
Dexone
Dexone 0.5
Dexone 0.75
Dexone 1.5
Dexone 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
Dxms
ECR Brand of Dexamethasone
EINECS 200-003-9
FT-0080377
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy Brand of Dexamethasone
Gammacorten
HL-dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
Hexadecadrol
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Hexadrol elixir
Hl-Dex
Hl-dex
I06-1196
ICN Brand of Dexamethasone
IontoDex
Isopto-Dex
Isopto-dex
LS-7300
Lokalison F
Lokalison f
Loverine
Luxazone
MK 125
MLS001055412
MLS001332507
MLS001332508
Maxidex
Maxidex Ont 0.1%
Maxidex Sus 0.1%
Maxitrol
Mediamethasone
Merck Brand of Dexamethasone
Merz Brand 1 of Dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MolMap_000018
MolPort-003-846-433
Mymethasone
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
NCI60_003067
NSC 34521
NSC34521
Naquasone (veterinary)
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
OTO-104
Ocu-Trol
Ocu-trol
Oradexon
PHL-dexamethasone
PMS-dexamethasone
Pet Derm III
Pet Derm Iii
Pet derm III
Pet-Derm Iii
Pms Dexamethasone Elixir 0.5mg/5ml
Policort
Posurdex
Prednisolon F
Prednisolon f
Prednisolone F
Prednisolone f
Prodex
S1322_Selleck
SAM002548948
SGCUT00126
SK-Dexamethasone
SK-dexamethasone
SMP1_000092
SMR000857119
SMR001227192
ST50307091
Sandoz dexamethasone
Sk-Dexamethasone
Spectrum5_002019
Spoloven
Sunia Sol D
Sunia sol D
Superprednol
TL8003317
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
alpha -Fluoro-16-alpha -methylcortisol
delta(Sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
dexamethasone
nchembio809-comp2
to_000038
5
LenograstimapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 11202135968-09-1
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
 
Granulocyte colony stimulating factor 3 (CHO cell derived)
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
6
EtoposideapprovedPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 1123233419-42-036462
Synonyms:
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
Ambap33419-42-0
BPBio1_000673
BRD-K37798499-001-02-5
BSPBio_000611
Bio1_000489
Bio1_000978
Bio1_001467
C01576
CCRIS 2392
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
EPE
EPEG
ETOP
Epipodophyllotoxin
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
 
Eposin, Vepesid, VP-16, Toposar, Etoposide
Etopol
Etopophos
Etopophos (phosphate salt)
Etoposid
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide [USAN:INN:BAN:JAN]
Etoposido
Etoposido [INN-Spanish]
Etoposidum
Etoposidum [INN-Latin]
Etosid
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
LS-1214
Lastet
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
NK 171
NSC 141540
NSC-141540
NSC141540
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Prestwick_211
S1225_Selleck
SAM001246880
SMR000112002
SPBio_002532
ST056353
Toposar
UNII-6PLQ3CP4P3
VP 16
VP 16 (pharmaceutical)
VP 16-213
VP 16213
VP-16
VP-16-213
VePESID (TN)
VePesid
Vepesid
Vepesid J
Vepeside
ZINC03830818
ZINC03938684
Zuyeyidal
etoposide
nchembio.573-comp8
nchembio873-comp2
trans-Etoposide
7
Bortezomibapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1794179324-69-7387447, 93860
Synonyms:
179324-69-7
AC1L8TUW
Bortezomib
Bortezomib (JAN/USAN/INN)
CHEBI:287372
CHEBI:41143
CHEMBL325041
CID387447
D03150
DB07475
DPBA
FT-0082488
I14-3268
LDP-341
LDP341
LPD 341
LPD-341
 
MLN341
MolPort-003-845-298
N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
NCI60_029010
NSC-681239
NSC681239
PROSCRIPT BORONIC ACID
PS-341
Pyz-Phe-boroLeu
S1013_Selleck
SBB071337
Velcade
Velcade (TN)
Velcade, MG-341, PS-341, Bortezomib
[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
bortezomib
8
MethotrexateapprovedPhase 4, Phase 2, Phase 115181959-05-2, 59-05-2126941
Synonyms:
4-amino-10-methylfolic acid
4-amino-N(10)-Methylpteroylglutamic acid
Abitrexate
Amethopterin
Amethopterine
Antifolan
Arbitrexate
Emtexate
Folex
HDMTX
L-Amethopterin
Ledertrexate
MTX
Metatrexan
 
Methopterin
Methotextrate
Methotrate
Methotrexat
Methotrexate Sodium
Methotrexatum
Methylaminopterin
Methylaminopterinum
Metotrexato
Mexate
Méthotrexate
N-Bismethylpteroylglutamic Acid
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Rheumatrex
Trexall
9
Cyclophosphamideapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1282950-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
10
Prednisoloneapproved, vet_approvedPhase 4, Phase 2, Phase 1115350-24-85755
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bio-0666
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
CO-Hydeltra
CPD000718761
Co-Hydeltra
Codelcortone
Cordrol
Cortalone
Cotogesic
Cotolone
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
Delta(1)-dehydrohydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Delta-Ef-Cortelan
Delta-Stab
Delta-stab
Deltacortenol
Deltacortril
Deltacortril Enteric
Deltahydrocortisone
Deltasolone
Deltisilone
Depo-Medrol
Derpo PD
Derpo Pd
Dexa-Cortidelt Hostacortin H
Dexa-Cortidelt hostacortin H
Di Adreson F
Di-Adreson F
Di-Adreson-F
Di-adreson F
DiAdresonF
Dicortol
Donisolone
Dydeltrone
EINECS 200-021-7
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
HSDB 3385
Hostacortin H
Hydeltra
Hydeltra-Tba
Hydeltrasol
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
I-Pred
Inflamase Forte
Inflamase Mild
K 1557
Key-Pred
Klismacort
LMST02030179
LS-7669
Lentosone
Lite Pred
M-Predrol
 
MLS001304083
MLS002154250
MLS002207037
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meti-Derm
Meticortelone
Metreton
MolPort-002-507-147
NCGC00179649-01
NSC 9120
NSC9120
NSC9900
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
PRDL
PRED-G
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Predni-Dome
Prednicen
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone (JP15/USP/INN)
Prednisolone (anhydrous)
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolone [INN:BAN:JAN]
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Prestwick_404
Rolisone
S1737_Selleck
SAM002264639
SMR000718761
SPBio_002367
Scherisolon
Solone
Steran
Sterane
Sterolone
Supercortisol
UNII-9PHQ9Y1OLM
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
Ultracortene-hydrogen
ZINC03833821
component of Ataraxoid
component of K-Predne-Dome
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
prednisolone
11
Methylprednisoloneapproved, vet_approvedPhase 4, Phase 2, Phase 1115383-43-26741
Synonyms:
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6-Methylprednisolone
6-alpha-Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
AC1L1N7A
Artisone-Wyeth
Artisone-wyeth
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
Besonia
Bio-0658
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
LMST02030178
LS-118498
Lemod
M0639_SIGMA
M1665
MEPRDL
MLS000028541
MLS001148159
MLS002207191
Medesone
Medixon
Medlone 21
 
Medrate
Medrol
Medrol (TN)
Medrol Adt Pak
Medrol Dosepak
Medrol adt pak
Medrol dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [DCIT]
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
NSC-19987
NSC19987
Nirypan
Noretona
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Prestwick_622
Promacortine
Reactenol
S1733_Selleck
SAM002589984
SMR000058330
SPBio_002377
Sieropresol
Solomet
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
delta(1)-6alpha-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
methylprednisolone
methylprenisolone
12
Prednisoneapproved, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1135953-03-25865
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
ACon0_000082
ACon1_000297
AI3-52939
Adasone
Ancortone
Apo-Prednisone
Apo-prednisone
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
Betapar
Bicortone
Bio-0649
C07370
C21H26O5
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
CPD001227202
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
DB00635
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta E.
Delta-Cortelan
Delta-Dome
Delta-cortelan
Delta-cortisone
Delta-cortone
Delta-dome
Deltacortene
Deltacortisone
Deltacortone
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Di-Adreson
Diadreson
EINECS 200-160-3
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fernisone
Fiasone
HMS1568O15
HMS2090J13
HSDB 3168
Hostacortin
In-Sone
Incocortyl
 
Juvason
Kortancyl
LMST02030180
LS-1325
Liquid Pred
Lisacort
Lodotra
MEGxm0_000443
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
Me-Korti
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI-C04897
NCI60_000008
NSC 10023
NSC10023
Nisona
Nizon
Novoprednisone
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
PRD
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Precort
Predeltin
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Prednison
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone Intensol
Prednisone [INN:BAN]
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Prestwick_405
Pronison
Pronisone
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
SK-Prednisone
SMR000718760
SMR001227202
SPBio_002214
Servisone
Sone
Sterapred
Supercortil
U 6020
UNII-VB0R961HZT
Ultracorten
Ultracortene
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Winpred
Wojtab
ZINC03875357
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
delta cortelan
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
delta-Cortisone
delta-Cortone
13
Folic Acidapproved, nutraceutical, vet_approvedPhase 4, Phase 2, Phase 1, Early Phase 1427959-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
14Antimetabolites, AntineoplasticPhase 4, Phase 3, Phase 2, Phase 17171
15Dermatologic AgentsPhase 4, Phase 3, Phase 2, Phase 15674
16Autonomic AgentsPhase 4, Phase 3, Phase 2, Phase 19774
17AntimetabolitesPhase 4, Phase 3, Phase 2, Phase 111774
18AntibodiesPhase 4, Phase 2, Phase 1, Early Phase 16045
19Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 110884
20Anti-Infective AgentsPhase 4, Phase 3, Phase 1, Phase 221402
21Folic Acid AntagonistsPhase 4, Phase 2, Phase 1, Early Phase 12200
22ImmunoglobulinsPhase 4, Phase 2, Phase 1, Early Phase 16045
23Protective AgentsPhase 4, Phase 2, Phase 17190
24Vitamin B ComplexPhase 4, Phase 2, Phase 1, Early Phase 14229
25Alkylating AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14694
26Antilymphocyte SerumPhase 4, Phase 2, Phase 3, Phase 1399
27Nucleic Acid Synthesis InhibitorsPhase 4, Phase 2, Phase 1, Early Phase 14855
28Antirheumatic AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 110627
29Antineoplastic Agents, AlkylatingPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14474
30Angiogenesis Modulating AgentsPhase 4, Phase 1, Phase 24072
31BB 1101Phase 4, Phase 3, Phase 2, Phase 12084
32HIV Protease InhibitorsPhase 4, Phase 3, Phase 2, Phase 15319
33Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 112778
34HormonesPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 113979
35Angiogenesis InhibitorsPhase 4, Phase 1, Phase 24143
36Gastrointestinal AgentsPhase 4, Phase 3, Phase 2, Phase 18109
37Antineoplastic Agents, HormonalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 15407
38Dexamethasone 21-phosphatePhase 4, Phase 3, Phase 2, Phase 12084
39Dexamethasone acetatePhase 4, Phase 3, Phase 2, Phase 120841177-87-3
40Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 112767
41glucocorticoidsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14920
42AntiemeticsPhase 4, Phase 3, Phase 2, Phase 13888
43Etoposide phosphatePhase 4, Phase 2, Phase 3, Phase 1, Early Phase 11232
44Anti-Inflammatory AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 110355
45Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 112770
46Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 122776
47
protease inhibitorsPhase 4, Phase 3, Phase 2, Phase 15320
Synonyms:
 
protease inhibitors
48Prednisolone hemisuccinatePhase 4, Phase 2, Phase 11153
49Prednisolone phosphatePhase 4, Phase 2, Phase 11153
50Prednisolone acetatePhase 4, Phase 2, Phase 11153

Interventional clinical trials:

(show top 50)    (show all 446)
idNameStatusNCT IDPhase
1Bone Marrow Transplantation in Treating Patients With Hematologic CancerCompletedNCT00003398Phase 4
2The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström MacroglobulinemiaRecruitingNCT02844322Phase 4
3Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström MacroglobulinemiaRecruitingNCT02844361Phase 4
4The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WMRecruitingNCT02844309Phase 4
5Rituximab (RTX) Therapy in Patients With Active TAORecruitingNCT02378298Phase 4
6Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's LymphomaUnknown statusNCT00003924Phase 3
7Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic PainUnknown statusNCT01316744Phase 3
8Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile NeutropeniaUnknown statusNCT00445497Phase 3
9Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström MacroglobulinemiaCompletedNCT00566332Phase 3
10Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic LymphomaCompletedNCT00608374Phase 3
11Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell TransplantationCompletedNCT00031668Phase 3
12Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for CancerCompletedNCT00070382Phase 3
13Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By ChemotherapyCompletedNCT00003341Phase 3
14Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical TrialCompletedNCT00750009Phase 3
15Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer PainCompletedNCT00666211Phase 3
16Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With CancerCompletedNCT00661999Phase 3
17Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer TreatmentCompletedNCT00008359Phase 3
18Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer PatientsCompletedNCT00003938Phase 3
19Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell CountCompletedNCT00003805Phase 3
20Treatment for Chronic Pain in Patients With Advanced CancerCompletedNCT00003687Phase 3
21American Ginseng in Treating Patients With Fatigue Caused by CancerCompletedNCT00719563Phase 3
22Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
23Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other DiseasesCompletedNCT00438958Phase 3
24Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer TreatmentCompletedNCT00006348Phase 3
25St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for CancerCompletedNCT00005805Phase 3
26Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's MacroglobulinemiaRecruitingNCT01788020Phase 3
27Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus CarriersRecruitingNCT02991638Phase 3
28Ibrutinib With Rituximab in Adults With Waldenström's MacroglobulinemiaActive, not recruitingNCT02165397Phase 3
29A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With SubcutaneoActive, not recruitingNCT01461928Phase 3
30First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.Active, not recruitingNCT00801281Phase 3
31Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell TransplantActive, not recruitingNCT01231412Phase 3
32Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic CancerActive, not recruitingNCT00075478Phase 3
33Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic CancerActive, not recruitingNCT00003816Phase 2, Phase 3
34Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin LymphomasTerminatedNCT01732926Phase 3
35Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin LymphomasTerminatedNCT01732913Phase 3
36A Study of Belimumab in Treating Symptomatic Waldenstroms MacroglobulinaemiaUnknown statusNCT01142011Phase 2
37Beta Alethine in Treating Patients With Waldenstrom's MacroglobulinemiaUnknown statusNCT00041379Phase 1, Phase 2
38Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's MacroglobulinemiaUnknown statusNCT01046006Phase 2
39Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's MacroglobulinemiaUnknown statusNCT00003512Phase 2
40Rituximab in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic CancerUnknown statusNCT01044745Phase 2
41Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That is Resistant to ChemotherapyUnknown statusNCT01035463Phase 1, Phase 2
42Comparison of Fludarabine Plus Total-Body Irradiation With Combination Chemotherapy Followed by Donor Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaUnknown statusNCT00041288Phase 2
43Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple MyelomaUnknown statusNCT00937183Phase 1, Phase 2
44Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell CancersUnknown statusNCT00003163Phase 2
45Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's LymphomaUnknown statusNCT00397800Phase 1, Phase 2
46Vaccine Therapy and GM-CSF in Treating Patients With CNS LymphomaUnknown statusNCT00621036Phase 2
47Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic LeukemiaUnknown statusNCT01016990Phase 2
48Sildenafil Citrate in Waldenstrom's MacroglobulinemiaCompletedNCT00165295Phase 2
49Bortezomib (Velcade) in Waldenstrom's MacroglobulinemiaCompletedNCT00142129Phase 2
50Perifosine in Patients With Relapsed/Refractory Waldenstrom's MacroglobulinemiaCompletedNCT00422656Phase 2

Search NIH Clinical Center for Waldenstrom Macroglobulinemia

Inferred drug relations via UMLS67/NDF-RT45:

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Waldenstrom Macroglobulinemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Waldenstrom Macroglobulinemia:
Blood stem cell transplantation for hematological diseases
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Waldenstrom Macroglobulinemia:
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived hematopoietic stem cells


Cochrane evidence based reviews: waldenstrom macroglobulinemia

Genetic Tests for Waldenstrom Macroglobulinemia

About this section

Genetic tests related to Waldenstrom Macroglobulinemia:

id Genetic test Affiliating Genes
1 Waldenstrom Macroglobulinemia26

Anatomical Context for Waldenstrom Macroglobulinemia

About this section

MalaCards organs/tissues related to Waldenstrom Macroglobulinemia:

35
B cells, Bone, Bone marrow, T cells, Kidney, Liver, Endothelial

Animal Models for Waldenstrom Macroglobulinemia or affiliated genes

About this section

MGI Mouse Phenotypes related to Waldenstrom Macroglobulinemia:

40
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053976.7CD27, CD40, CD40LG, CXCR4, ITGA4, ITGAE
2MP:00053876.0CD27, CD40, CD40LG, CXCR4, ITGA4, ITGAE

Publications for Waldenstrom Macroglobulinemia

About this section

Articles related to Waldenstrom Macroglobulinemia:

(show top 50)    (show all 127)
idTitleAuthorsYear
1
Prospective, multicenter clinical trial of everolimus as primary therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). (27836860)
2016
2
Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells. (27813535)
2016
3
Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection. (26942591)
2016
4
Characteristic OCT Pattern in Waldenstrom Macroglobulinemia. (25871872)
2015
5
Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. (26139427)
2015
6
Waldenstrom macroglobulinemia: prognosis and management. (25815903)
2015
7
Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib. (25060991)
2014
8
Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. (24716234)
2014
9
Waldenstrom macroglobulinemia: genetics dictates clinical course. (24786453)
2014
10
A single-arm, phase II study of the anti-Blys monoclonal antibody belimumab in symptomatic Waldenstrom macroglobulinemia. (23773449)
2013
11
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). (24004667)
2013
12
A new era for Waldenstrom macroglobulinemia: MYD88 L265P. (23723443)
2013
13
Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia. (22896002)
2012
14
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. (21732338)
2012
15
Waldenstrom macroglobulinemia with a durable clinical response to epoetin beta. (22260157)
2012
16
Family history of non-hematologic cancers among Waldenstrom macroglobulinemia patients: a preliminary study. (22099500)
2012
17
A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemia. (22879385)
2012
18
Second malignancies among Waldenstrom macroglobulinemia patients: small samples and sparse data. (22100692)
2012
19
Progression in smoldering Waldenstrom macroglobulinemia: long-term results. (22451426)
2012
20
Residual monotypic plasma cells in patients with waldenstrom macroglobulinemia after therapy. (21350089)
2011
21
Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia. (21220746)
2011
22
Successful treatment of eosinophilic colitis by montelukast sodium plus budesonide in a patient with Waldenstrom macroglobulinemia. (21575902)
2011
23
Targeting the bone marrow in Waldenstrom macroglobulinemia. (22035751)
2011
24
The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia. (21681781)
2011
25
Establishment and characterization of a novel Waldenstrom macroglobulinemia cell line, MWCL-1. (21415268)
2011
26
microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia. (20519629)
2010
27
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. (20142586)
2010
28
High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. (20368570)
2010
29
Successful treatment with rituximab and thalidomide of POEMS syndrome associated with Waldenstrom macroglobulinemia. (20673674)
2010
30
Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. (20181958)
2010
31
Novel agents in Waldenstrom Macroglobulinemia. (22844582)
2010
32
Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia. (19220283)
2009
33
Simultaneously significant hepatic and mild splenic uptake of Tc-99m MDP resulting from Waldenstrom macroglobulinemia. (19542951)
2009
34
SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. (18448868)
2008
35
Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. (18703425)
2008
36
Fludarabine, cyclophosphamide and rituximab (FCR) induced pulmonary hypertension in Waldenstrom macroglobulinemia. (18452089)
2008
37
Thalidomide and rituximab in Waldenstrom macroglobulinemia. (18713945)
2008
38
CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia. (18216294)
2008
39
Clinical relevance of soluble HLA class I molecules in Waldenstrom Macroglobulinemia. (18331603)
2008
40
Intestinal lymphangiectasia with protein-losing enteropathy in Waldenstrom macroglobulinemia. (17632262)
2007
41
Impaired class switch recombination (CSR) in Waldenstrom macroglobulinemia (WM) despite apparently normal CSR machinery. (16317092)
2006
42
The amino acid sequence of an AL-protein, AL-KH, isolated from the heart of a patient with Waldenstroms macroglobulinemia and amyloidosis. (17107886)
2006
43
Lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia: an evolving concept. (16210920)
2005
44
Two cases of chronic lymphoproliferative disorders in psoriatic patients treated with cyclosporine: hairy cell leukemia and Waldenstrom macroglobulinemia. (16048757)
2005
45
Disseminated Nocardia asteroides presenting as pulmonary non-caseating granulomas in a patient with Waldenstrom macroglobulinemia. (11876515)
2002
46
Simultaneous occurrence of polycythemia vera and Waldenstrom macroglobulinemia: a case report and review of the literature. (12243551)
2002
47
Cutaneous Waldenstrom macroglobulinemia in transformation. (10218675)
1999
48
Occurrence of heavy chain of 7S IgM half-molecule whose NH2-terminal sequence is identical with that of kappa light chain sequence in patients with Waldenstrom macroglobulinemia. (10340436)
1999
49
A case of t(8;14) with total and partial trisomy 3 in Waldenstrom macroglobulinemia. (9595048)
1998
50
Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. (8093333)
1993

Variations for Waldenstrom Macroglobulinemia

About this section

Expression for genes affiliated with Waldenstrom Macroglobulinemia

About this section
Search GEO for disease gene expression data for Waldenstrom Macroglobulinemia.

Pathways for genes affiliated with Waldenstrom Macroglobulinemia

About this section

Pathways related to Waldenstrom Macroglobulinemia according to GeneCards Suite gene sharing:

(show all 27)
idSuper pathwaysScoreTop Affiliating Genes
19.8CD40, CD40LG
29.8CD40, CD40LG
39.7MYD88, PRKCB
49.6CD40, CD40LG, MYD88
59.5CD40, CD40LG, ZAP70
69.5CD40, CD40LG, ZAP70
79.3CD27, CD40, CD40LG
8
Show member pathways
9.1CD40, CD40LG, IGHM, ZAP70
9
Show member pathways
9.0CD27, CD40, CD40LG, MYD88
109.0CD40, CD40LG, ITGA4
119.0CD40, CD40LG, ITGA4
12
Show member pathways
9.0CD40, CD40LG, PRKCB, ZAP70
138.9ITGA4, ITGAE, ZAP70
14
Show member pathways
8.8CD27, CD40, CD40LG, PRKCB
158.7CD40, CD40LG, MYD88, PRKCB, ZAP70
16
Show member pathways
8.7CD40, CD40LG, MYD88, PRKCB, ZAP70
178.7ITGA4, ITGAE, PRKCB
188.7CD40LG, CXCR4, MYD88, PAX5, ZAP70
19
Show member pathways
8.4CD40, CD40LG, CXCR4, ITGA4
208.4CD27, CD40, CD40LG, CXCR4, PAX5
218.2CD40, CD40LG, ITGA4, ITGAE, PAX5
22
Show member pathways
8.2CD40, CD40LG, ITGA4, MYD88, PRKCB
23
Show member pathways
8.2CD27, CD40, CD40LG, CXCR4, PRKCB
24
Show member pathways
8.2CD27, CD40, CD40LG, CXCR4, PRKCB
25
Show member pathways
6.9CD27, CD40, CD40LG, IGHM, ITGA4, MYD88
26
Show member pathways
6.5CD27, CD40, CD40LG, CXCR4, ITGA4, ITGAE
27
Show member pathways
6.3CD27, CD40, CD40LG, CXCR4, ITGA4, ITGAE

GO Terms for genes affiliated with Waldenstrom Macroglobulinemia

About this section

Cellular components related to Waldenstrom Macroglobulinemia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1external side of plasma membraneGO:00098978.8CD27, CD40, CD40LG, IGHM, ITGAE
2cell surfaceGO:00099867.6CD27, CD40, CD40LG, CXCR4, IGHM, ITGA4
3plasma membraneGO:00058865.5CD27, CD40, CD40LG, CXCR4, HAS1, IGHM

Biological processes related to Waldenstrom Macroglobulinemia according to GeneCards Suite gene sharing:

(show all 19)
idNameGO IDScoreTop Affiliating Genes
1regulation of immunoglobulin secretionGO:005102310.4CD40, CD40LG
2positive regulation of interleukin-12 productionGO:003273510.4CD40, CD40LG
3positive regulation of endothelial cell apoptotic processGO:200035310.3CD40, CD40LG
4B cell proliferationGO:004210010.3CD40, CD40LG
5immunoglobulin mediated immune responseGO:001606410.3CD27, MYD88
6positive regulation of B cell differentiationGO:004557910.2CD27, ZAP70
7leukocyte cell-cell adhesionGO:00071599.9CD40LG, ITGA4
8tumor necrosis factor-mediated signaling pathwayGO:00332099.8CD27, CD40, CD40LG
9positive regulation of I-kappaB kinase/NF-kappaB signalingGO:00431239.7CD40, MYD88, PRKCB
10B cell receptor signaling pathwayGO:00508539.7IGHM, PRKCB, ZAP70
11response to lipopolysaccharideGO:00324969.6CD27, CD40, MYD88
12adaptive immune responseGO:00022509.5IGHM, PRKCB, ZAP70
13B cell activationGO:00421139.5CD40, PRKCB, ZAP70
14positive regulation of NF-kappaB transcription factor activityGO:00510929.4CD40, CD40LG, MYD88, PRKCB
15regulation of immune responseGO:00507769.4CD40, CD40LG, ITGA4
16platelet activationGO:00301689.2CD40, CD40LG, PRKCB
17cellular response to cytokine stimulusGO:00713459.0CXCR4, ITGA4
18regulation of cell proliferationGO:00421279.0CD27, CD40, MYD88
19inflammatory responseGO:00069548.2CD27, CD40, CD40LG, CXCR4, MYD88, ZAP70

Molecular functions related to Waldenstrom Macroglobulinemia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1tumor necrosis factor-activated receptor activityGO:00050319.7CD27, CD40
2coreceptor activityGO:00150269.0CXCR4, ITGA4
3antigen bindingGO:00038238.8CD40, IGHM, ITGA4

Sources for Waldenstrom Macroglobulinemia

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet